Abstract��
OBJECTIVE To develop a therapeutic drug monitoring software of vancomycin for adult patients to help physician for personalized use of vancomycin. METHODS A system literature retrieval search was conducted in the PubMed database to collect the population pharmacokinetic studies published before September 2012. A set of therapeutic drug monitoring models for vancomycin was assembled by the models included in the above literatures and the model developed by the authors. Based on the Bayesian principle, a therapeutic drug monitoring software built upon these population pharmacokinetic models was developed with C++ in the integrated development environment (Microsoft Visual Studio 2005). RESULTS The set of therapeutic drug monitoring models included 14 population pharmacokinetic analyses. The software developed on these pharmacokinetic models could be applied to conduct population, subpopulation and individual predictions, thus help clinician in their individualized treatments. CONCLUSION This study developed software covers the current reported vancomycin pharmacokinetic model. Clinician can choose the appropriate model according to the actual situation of the patients.
DENG Chen-Hui-,
JI Shuang-Min-,
WANG Si-Yuan- etc
.Development of Therapeutic Drug Monitoring Software of Vancomycin for Adult Patients[J] Chinese Pharmaceutical Journal, 2014,V49(10): 881-885
��
[1]
MARTIN J H, NORRIS R, BARRAS M, et al. Therapeutic monitoring of vancomycin in adult patients:A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev, 2010, 31(1):21-24.[2] RYBAK M, LOMAESTRO B, ROTSCHAFER J C, et al. Therapeutic monitoring of vancomycin in adult patients:A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm, 2009, 66(1):82-98.[3] AN S Y, HWANG E K, KIM J H, et al. Vancomycin-associated spontaneous cutaneous adverse drug reactions. Allergy Asthma Immunol Res, 2011, 3(3):194-198.[4] HOLFORD N H. Target concentration intervention:beyond Y2K. Br J Clin Pharmacol, 2001, 52(suppl 1):55-59.[5] ZHANG Y D, ZHENG Z H, JIN Y, et al. DUE analysis and evaluation of vancomycin in the ortloopedic department Chin Pharm J(�й�ҩѧ��־), 2012, 47(24):2043-2044.[6] MATTHEWS I, KIRKPATRICK C,HOLFORD N. Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol, 2004, 58(1):8-19.[7] HENNIG S, NORRIS R,KIRKPATRICK C M. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis����a population pharmacokinetic study. Br J Clin Pharmacol, 2008,65(4):502-510.[8] DENG C H, ZHANG G M, BI S S, et al. Therapeutic drug monitoring software of tacrolimus for Chinese renal transplant patients. Chin Pharm J(�й�ҩѧ��־), 2010, 45(10):775-779.[9] DENG C H, ZHANG G M, BI S S, et al. The therapeutic drug monitoring network server of tacrolimus for Chinese renal transplant patients. Acta Pharm Sin(ҩѧѧ��), 2011, 46(7):828-833.[10] ZHANG G M, LI L, CHEN W Q, et al. Population pharmacokinetics of tacrolimus in Chinese renal transplant patients. Acta Pharm Sin(ҩѧѧ��), 2008, 43(7):695-701.[11] DENG C H, LIU T T, ZHOU T Y, et al. Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis. Int J Clin Pharmacol Ther, 2013, 51(5):407-415.[12] MARSOT A, BOULAMERY A, BRUGUEROLLE B, et al. Vancomycin:A review of population pharmacokinetic analyses. Clin Pharmacokinet, 2012, 51(1):1-13.[13] BUELGA D S, DEL MAR FERNANDEZ DE GATTA M, HERRERA E V, et al. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother, 2005, 49(12):4934-4941.[14] MULLA H, OOBONI S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol, 2005, 60(3):265-275.[15] DOLTON M, XU H, CHEONG E, et al. Vancomycin pharmacokinetics in patients with severe burn injuries. Burns, 2010, 36(4):469-476.[16] LLOPIS-SALVIA P,JIMENEZ-TORRES N V. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther, 2006, 31(5):447-454.[17] ROBERTS J A, TACCONE F S, UDY A A, et al. Vancomycin dosing in critically ill patients: Robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother, 2011, 55(6):2704-2709.[18] PURWONUGROHO T A, CHULAVATNATOL S, PREECHAGOON Y, et al. Population pharmacokinetics of vancomycin in Thai patients. Sci World J, 2012, 2012:762649.[19] YASUHARA M, IGA T, ZENDA H, et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit, 1998, 20(2):139-148.[20] YAMAMOTO M, KUZUYA T, BABA H, et al. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther, 2009, 34(4):473-483.[21] TANAKA A, AIBA T, OTSUKA T, et al. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother, 2010, 54(2):778-782.[22] REVILLA N, MARTIN-SUAREZ A, PEREZ M P, et al. Vancomycin dosing assessment in intensive care unit patients based on a populationpharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol, 2010, 70(2):201-212.[23] SANCHEZ J L, DOMINGUEZ A R, LANE J R, et al. Population pharmacokinetics of vancomycin in adult and geriatric patients:Comparison of eleven approaches. Int J Clin Pharmacol Ther, 2010, 48(8):525-533.[24] STAATZ C E, BYRNE C,THOMSON A H. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. Br J Clin Pharmacol, 2006, 61(2):164-176.
2014, Vol. 49 